Clinical Validation of a Predictive Test for Postpartum Depression

"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."